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Impact of time-of-flight PET on
quantification accuracy and lesion
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MRI for prostate cancer
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Abstract
Background: Accurate attenuation correction (AC) is an inherent problem of positron emission tomography magnetic
resonance imaging (PET/MRI) systems. Simulation studies showed that time-of-flight (TOF) detectors can reduce PET
quantification errors in MRI-based AC. However, its impact on lesion detection in a clinical setting with 18F-choline has
not yet been evaluated. Therefore, we compared TOF and non-TOF 18F-choline PET for absolute and relative difference
in standard uptake values (SUV) and investigated the detection rate of metastases in prostate cancer patients.
Results: Non-TOF SUV was significantly lower compared to TOF in all osseous structures, except the skull, in primary
lesions of the prostate, and in pelvic nodal and osseous metastasis. Concerning lymph node metastases, both
experienced readers detected 16/19 (84%) on TOF PET, whereas on non-TOF PET readers 1 and 2 detected 11 (58%),
and 14 (73%), respectively. With TOF PET readers 1 and 2 detected 14/15 (93%) and 11/15 (73%) bone metastases,
respectively, whereas detection rate with non-TOF PET was 73% (11/15) for reader 1 and 53% (8/15) for reader 2. The
interreader agreement was good for osseous metastasis detection on TOF (kappa 0.636, 95% confidence interval [CI] 0.
453–0.810) and moderate on non-TOF (kappa = 0.600, CI 0.438–0.780).
Conclusion: TOF reconstruction for 18F-choline PET/MRI shows higher SUV measurements compared to non-TOF
reconstructions in physiological osseous structures as well as pelvic malignancies. Our results suggest that addition of TOF
information has a positive impact on lesion detection rate for lymph node and bone metastasis in prostate cancer patients.
Keywords: PET/MRI, Attenuation correction, Time-of-flight, Prostate cancer
Background
Direct combination of magnetic resonance imaging (MRI)
with positron emission tomography (PET) is a recent
advance in hybrid imaging, and the demand for such im-
aging is continuously growing. Early clinical experience
showed comparable results of PET/MRI in the detection
of malignant lesion compared to PET/computed tomog-
raphy (CT) [1]. However, a major advantage of hybrid
PET/MRI is the combination of high soft tissue contrast
and multi-parameter images from MR with functional and
molecular information from PET, which could be espe-
cially beneficial in the pelvis, as was suggested by several
authors [2–4].
In high-risk patients or patients with the suspicion of
extra pelvic diseases, use of PET/CT with either 18F-choline
or more recently also 68Ga-PSMA is widely used and
showed improved accuracy compared to morphologic
imaging alone [5]. Studies comparing 18F-choline PET/CT
and PET/MRI yielded highly comparable results
concerning lesion detection and choline uptake in patients
with prostate cancer [6–9] with the benefit of improved
anatomical localization [7]. Furthermore, the advantages
of improved tracer localization in Choline PET/MRI
* Correspondence: urs.muehlematter@usz.ch
1Department of Diagnostic and Interventional Radiology, University Hospital
Zurich, Zurich, Switzerland
2Department of Nuclear Medicine, University Hospital Zurich, Zurich,
Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Mühlematter et al. EJNMMI Research  (2018) 8:41 
https://doi.org/10.1186/s13550-018-0390-8
could even improve accuracy of local staging over
multiparametric MRI alone [10–12]. Therefore, PET/MRI
is a highly promising field for prostate cancer.
Attenuation correction (AC) of PET remains an inher-
ent problem of quantitative PET/MRI imaging since it is
based on either an atlas-based (brain) or a direct MR
image segmentation-based AC neglecting metal or bone
density. Newer template-based AC algorithms including
pattern recognition/machine learning and transmission/
emission-based methods have recently been incorpo-
rated into magnetic resonance-based attenuation correc-
tion (MRAC) but are not clinically available [13, 14]. It
has been demonstrated that segmentation-based MRAC,
which is the standard method on most commercial PET/
MRI scanners, treating bone as soft tissue, leads to sub-
stantial underestimation of SUV in bone lesions [15–20].
A recent simulation study showed that TOF PET can re-
duce MRAC-induced quantification errors in bone tissue
[21]. However, it remains unclear if this reduced
MRAC-induced bias on SUV measurements has clinical
consequences for 18F-choline PET/MRI in prostate
cancer patients.
An important improvement in PET was the devel-
opment of the time-of-flight (TOF) function which
was initially introduced in the clinical setting in the
1980s [22]. Since then, PET technique has substan-
tially improved resulting in fully-3D TOF PET scan-
ners available today [23]. With the development of
new PET detector systems, there are now fully
integrated PET/MRI systems available featuring TOF.
Previous studies have shown that TOF information
improves image quality of PET/CT [24–28] and PET/
MRI [29–31]. For example, the implementation of
TOF in PET/MRI notably reduces image acquisition
time [32], metal artifacts [31, 33–35], as well as arti-
facts caused by respiratory mismatch between emis-
sion and data [21, 36]. Using the same TOF PET
images from PET/CT with MRI or CT in a trimodal-
ity setting showed that the PET/CT and PET/MRI
performed comparable in whole-body oncology [37],
but for PET/MRI, the addition of TOF improved le-
sion quantification [38]. However, studies comparing
TOF and non-TOF PET/MRI addressing specific
tumor entities are still rare.
Thus, the purpose of our study was to examine the
impact of TOF versus non-TOF reconstruction for 18F-
choline PET/MRI regarding absolute and relative
SUVmax differences and metastasis detection in the
setting of prostate cancer patients.
Table 1 MRI protocol parameters
Axial LAVA-FLEXa Coronal T2w FRFSE-XLb Axial T2w FRFSE-XL
(Pelvic)
Coronal T2w
FRFSE-XL
(Pelvic)
Axial DWIc
EPId (Focus) (Pelvic)
Repetition time, TR (ms) 5618 6326 2600 2900 4000
Echo time, TE (ms) 2.66 118 118 121 67.2
Flip angle, FA (degrees) 12 111 125 125 90
Acquisition matrix 344 × 256 288 × 224 416 × 224 416 × 224 160 × 80
Image size (voxels) 512 × 512 512 × 512 512 × 512 512 × 512 256 × 256
Reconstruction diameter (mm) 460 480 180 200 240
Slice thickness (mm) 3 (3D) 5 4 4 4
Signal averages 0.68 1 4 4 –
b-values (s/mm2) and signal averages – – – – 0 (6 av.)
400 (8 av.)
700 (16 av.)
Diffusion direction – – – – ‘All’
Bandwidth (Hz/pixel) 651 355 326 326 1953
Acquisition time (mm:ss) 0:18 0:52 3:39 4:04 5:16
a3D, fast spoiled gradient echo imaging technique that generates water only, fat only, in phase, and out of phase echoes in one single acquisition (GE Healthcare,
Waukesha, WI, USA)
bFast relaxation fast spin echo
cDiffusion-weighted imaging
dEcho-planar imaging
Table 2 Reference standard of lesions
Histology Clinical/imaging follow-up
Lymph node metastases 10 9a
Osseous metastases 0 15b
aMedian follow-up duration 276 days (range 188–364)
bMedian follow-up duration 189 days (range 74–410)
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Methods
Subjects
Twenty men referred to our department for an 18F-
choline PET/CT were prospectively enrolled in this
study from December 2014 to January 2016.There was
no further selection applied regarding patient inclusion.
Exclusion criteria were (a) refusal to study participation
or (b) claustrophobia or other contraindications for MRI
(e.g., cardiac pacemakers). Informed consent was
obtained from each patient prior to the study inclusion
and to the PET/MRI. The local ethics committee
approved the study under reference number KEK ZH-
Nr 2013-0220.
PET/MRI protocol
All patients underwent a single injection of 18F-choline
(mean dose ± standard deviation, 201 ± 4.7 MBq, range
195–214 MBq). Whole-body PET/MRI was performed
after 59.3 min ± 4.9 min (mean ± SD) after injection.
These PET/MRI study scans were acquired with a simul-
taneous TOF PET/MRI system (SIGNA PET/MR, GE
Healthcare, Waukesha, WI, USA) used in previous stud-
ies at our department [33]: The scanner comprises a 3T
wide-bore MR system with a TOF-PET detector ring in-
stalled between the body and gradient coils. The trans-
axial and axial fields of view are 600 and 250 mm,
respectively. The resolving time of the TOF detector is
less than 400 ps [39].
The default acquisition protocol consisted of six bed
positions (2 min per bed position), from the vertex of
the skull to the mid-thighs. During PET scanning, MRI
acquisitions for attenuation correction were performed,
using in-phase and out-of-phase images to calculate
water-only and fat-only images according to Dixon’s
method [40, 41]. Additionally, the basic whole-body
protocol and dedicated sequences to the pelvic region
were applied. The MRI protocols and parameters are
listed in Table 1.
MR imaging-based attenuation correction
An atlas-based attenuation correction was used for the
head [42]. For the remaining body regions, air, lung, and
soft tissue were segmented and a continuous fat-water
based MRAC method was applied [43, 44].
TOF and non-TOF PET reconstructions and image analysis
3D-PET emission data was reconstructed with TOF and
non-TOF for each patient with a fully three-dimensional
iterative algorithm, which is part of the manufacturer-
supplied standard scanner software (ordered subset
expectation maximization (OSEM)-based VUE Point FX
Table 3 Summary of patient characteristics
N % of N
Patients 20
Age at scan in years (median, range) 72.5 (60–89)
Body height in m (median, range) 1.74 (1.60–1.87)
Body weight in kg (median, range) 80 (57–114)
BMIa in kg/m2 (median, range) 27.5 (19.0–34.2)
Reason for referral
Restaging 11 55
Initial staging 9 45
Tumor location
No tumor detected 2 10
Prostate 14 70
Lymph node metastases 9 45
Osseous metastases 7 35
aBody mass index
Table 4 Average SUVmax and SUVmax difference (difference significant if p < 0.05)
Site TOF TOF SDa Non-TOF Non-TOF SDa n-TOF - TOF p value Highest value
Skull bone − 0.71 0.19 0.87 0.24 0.16 < 0.001 non-TOF
C7 3.88 0.81 3.51 0.81 − 0.37 0.050 NS
TH12 5.69 1.4 2.73 1.17 − 2.96 < 0.001 TOF
L5 4.99 1.48 3.56 1.32 − 1.43 < 0.001 TOF
Femoral head 0.98 0.68 0.53 0.61 − 0.45 < 0.001 TOF
Pelvic bone 4 1.26 3.3 1.24 − 0.7 0.003 TOF
Kidney 17.98 3.31 17 3.38 − 0.98 < 0.001 TOF
Ischioanal fossa 1.46 0.36 1.35 0.4 − 0.11 1 NS
M. gluteus 2.12 0.63 2.06 0.61 − 0.06 1 NS
Prostate lesion 8.42 2.41 7.34 2.44 − 1.08 < 0.001 TOF
Lymph node lesion 8.66 3.55 7.03 3.54 − 1.63 < 0.001 TOF
Osseous lesion 9.46 6.57 8.23 6.33 − 1.24 0.008 TOF
Units: g/ml
aStandard deviation
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for TOF PET and VUE Point HD for non-TOF PET, GE
Healthcare, Waukesha, WI, USA). Both algorithms
include standard scatter, dead-time, random attenuation,
and normalization correction as well as correction for
the detector response using Sharper (GE Healthcare,
Waukesha, WI, USA). Their only difference lies in the
TOF information, which is ignored by the VUE Point
HD algorithm. The PET images for both TOF and non-
TOF were reconstructed using 2 iterations, 28 subsets, a
600-mm field of view, and a 256 × 256 image grid with
2.34 × 2.34 × 2.78 mm3 voxels. For image space filtering,
an in-plane Gaussian convolution kernel with a full
width at half maximum of 4.0 mm was used, followed by
a standard axial filter with a 3-slice kernel.
Reconstructed images were reviewed on a dedicated
workstation (Advantage Workstation, Version 4.6, GE
Healthcare, Milwaukee, WI, USA) for region of interest
(ROI) analysis. Maximum standardized uptake values
(SUVmax) was normalized to patient body weight. SUV-
max was calculated for nine physiological structures using
rectangle ROIs of 20 × 20 mm: skull, C7, Th12, L5, fem-
oral head, pelvis, kidneys, ischioanal fossa, and M.
Table 5 Average relative SUVmax differences
Site (n-TOF -TOF)/TOF RSD
Skull bone 23% 0.16
C7 − 9% 0.12
TH12 − 52% 0.15
L5 − 28% 0.17
Femoral head − 48% 0.23
Pelvic bone − 18% 0.17
Kidney − 6% 0.04
Ischioanal fossa − 6% 0.2
M. gluteus − 1% 0.21
Prostate lesion − 13% 0.11
Lymph node lesion − 22% 0.13
Osseous lesion − 17% 0.10
RSD relative standard deviation
Fig. 1 Bland-Altman plots with mean (bold line) and twice the standard deviation (dotted lines) of relative difference of maximum standard uptake
value in soft tissue (a), bone (b), prostate cancer (c), lymph node metastases (d), and bone metastases (e). Note the good correlation of
TOF and non-TOF reconstructions in soft tissue and the high relative difference in bone and lesions
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gluteus. Average values were calculated for symmetrical
structures. Lesions in the prostate, lymph node, and
bone were assessed with size-adapted ROIs with know-
ledge of the reference standard. Additionally, size of
lymph node metastases (maximal short axis) as well
as minimum distance to osseous tissue (lymph node
surface to cortical bone) was measured on T2-
weighted MR images.
Four readers (readers 1 and 2, board-certified radi-
ologist with 2 and 1 years of fellowship training in
Nuclear Medicine; reader 3, 2 years of residency
training in Nuclear Medicine; reader 4, 3 years of
residency training in Radiology and 1 year of fellow-
ship training in Nuclear Medicine) reviewed all recon-
structed images on a dedicated review workstation.
Readers investigated non-TOF PET and 1–3 months
later TOF PET and were blinded to any other infor-
mation than the patient bodyweight and injected dose
(necessarily needed for the SUV calculations). Readers
1–4 evaluated the data for image quality, prostate le-
sions detection (or prostate bed if post-prostatectomy)
, lymph node metastases detection, and osseous and
visceral metastases detection. Image quality was
ranked from 4 (excellent) to 0 (non-diagnostic), and it
was evaluated based on general quality, image sharp-
ness, noise, and presence of artifacts (noise was evalu-
ated in a scale from 0 (high noise) to 4 (low noise),
artifacts from 0 (no artifacts) to 2 (severe artifacts),
respectively). Readers 1 and 2 furthermore evaluated exact
lymph node and osseous metastases site. An unblinded
read out (board-certified Nuclear Medicine Physician and
Radiologist), including all available histopathology and
clinical/imaging follow-up data served as a reference
standard. Details of the reference standard are shown in
Table 2.
Statistical analysis
Difference of SUVmax (SUVmax n-TOF − SUVmax TOF) was
compared using a two-sample paired t test and to
achieve an alpha of 0.05, a conservative multiple com-
parisons correction of Bonferroni was applied (n = 12
different ROIs compared in each patient) [45]. Signifi-
cant difference was defined at p < 0.05. Relative differ-
ence of SUVmax was defined as (SUVmax n-TOF − SUVmax
TOF)/SUVmax TOF and was compared using Bland Alt-
man plots [46]. Results are presented as mean and rela-
tive standard deviation (RSD). Agreement among
observers was evaluated using Fleiss’s kappa (κ) [47, 48]
for all readers. Interpretation of κ was based on a classi-
fication provided by Landis and Koch: 0.0, poor; 0.0–0.
20, slight; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.
80, good; 0.81–1.00, almost-perfect reproducibility [49].
The Spearman’s rank correlation was used to investi-
gate the effect of lymph node lesion size and the
distance between lymph node lesions and bone on rela-
tive SUVmax difference. Lesion detection percentage was
calculated for lymph node metastasis and distant metas-
tasis. The Wilcoxon signed-rank test was used to
Fig. 2 Coronal and sagittal TOF 18F-choline PET reconstruction
(a). Coronal and sagittal non-TOF 18F-choline PET reconstruction
(b). Relative percentage difference image (TOF - non-TOF)/TOF
(c). Note the differences in the vertebra, the pelvic region, and
the femora
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compare visual image quality scores between TOF and
non-TOF reconstructions. Neither sensitivity nor specifi-
city measurements were calculated due to the
heterogenous patient population and application of a
heterogenous reference standard. All analyses were con-
ducted in R 3.2.5 (The R Software Foundation, Vienna,
Austria).
Results
A total of 20 patients with a mean age of 72.5 years
(range 60–89 years) were consecutively included in
our study. Of these, 11 were referred for restaging
and 9 for initial staging of prostate cancer. Table 3
summarizes the demographic and clinically relevant
details of our study population. A total of 241 ROIs
were analyzed. One hundred eighty ROIs were set in
physiological tissue, 25 ROIs in prostate lesions, 19
ROIs in lymph node metastases, and 17 ROIs in osse-
ous metastases to calculate absolute and relative dif-
ferences. Our study population included 19 lymph
node metastases in nine patients. Seven patients had
bone metastases, two with disseminated disease. The
remaining five patients showed 15 osseous metastases.
In two patients, no cause for an elevated PSA could
be identified. An overview of absolute and relative
differences for physiological tissue and lesions are
given in Tables 4 and 5.
SUVmax was significantly lower in non-TOF recon-
structions compared to TOF images in all osseous struc-
tures, except in the bone of the skull with a mean
relative difference of osseous structures without skull
bone of − 31% (RSD ±23). However, there was no signifi-
cant difference in the pooled physiological soft tissue
data between non-TOF and TOF, although the difference
was significant for the kidney alone. Typical distribution
of relative differences in physiological tissue is shown in
Bland-Altman plots in Fig. 1a, b. The highest relative
difference of SUVmax was found in the Th12 and femoral
heads with a mean relative difference of − 52% (RSD ±
15) and − 48% (RSD ± 23), respectively. Examples for
relative difference images of TOF PET and non-TOF
PET reconstructions for one patient are given in Fig. 2.
Fig. 3 Relative maximum standard uptake value (SUV) differences for lymph node metastases according to lesion size (a) and distance of the
lesion from the bone (b). Note the increasing relative difference with decreasing distance from the bone and decreasing lesion size. The line
represents the Spearman’s rank correlation and ρ the Spearman’s rank correlation coefficient
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Lesions
SUVmax was significantly lower on non-TOF images
for all lesions, with an overall underestimation of −
17% (− 13% for prostate lesions, − 22% for lymph
node metastases, and − 17% for osseous metastases,
respectively). Typical distribution of relative differ-
ences of lesions is shown in Bland-Altman plots in
Fig. 1c, d, and e. Spearman’s rank correlation showed
a negative correlation for both lymph node lesion size
and their distance to bone to relative SUVmax differ-
ence (ρ = 0.4, p value = 0.09 and ρ = 0.52, p value = 0.
02, respectively) as shown in Fig. 3.
Detailed results of all four readers are given in Table 6.
Reader 1 detected 84% (16/19) of lymph node metasta-
ses on TOF PET reconstructions (three missed metasta-
ses with histopathology reference) and 58% (11/19) on
non-TOF PET reconstruction (five missed metastases
with histopathology, three with imaging/clinical follow-
up as reference, respectively). Reader 1 detected 93%
(14/15) of osseous metastases on TOF PET and 73% (11/
15) on non-TOF PET reconstructions (all missed metas-
tases with imaging/clinical follow-up as reference).
Reader 2 detected 84% (16/19) of lymph node metasta-
ses on TOF PET reconstructions (two missed metastases
with histopathology reference, one with imaging/clinical
follow-up as reference, respectively) and 73% (14/19) on
non-TOF PET reconstruction (three missed metastases
with histopathology, two with imaging/clinical follow-up
as reference, respectively). Reader 2 detected 73% (11/
15) of osseous metastases on TOF PET and 53% (8/15)
on non-TOF PET reconstructions (all missed metastases
with imaging/clinical follow-up as reference). Example
of a missed lymph node metastasis is given in Fig. 4.
The interreader agreement between readers 1 and 2 was
good for localization of lymph node metastases for TOF
and non-TOF (TOF kappa = 0.652, 95% confidence
interval [CI] 0.506–0.798 and non-TOF kappa = 0611, CI
0.465–0.757). The interreader agreement between
readers 1 and 2 was almost perfect for localization of os-
seous metastases for TOF (TOF kappa = 0.81, CI 0.631–
0.989) and good for non-TOF (non-TOF kappa = 0.756.
CI 0.577–0.935). Interreader agreement between all
reader was good for local cancer detection for both TOF
and non-TOF (TOF kappa = 0.762, CI 0.583–0.941 and
non-TOF kappa = 0.696, CI 0.517–0.875), respectively.
For lymph node metastasis detection, the agreement was
moderate for both TOF and non-TOF (TOF kappa 0.
501, CI 0.323–0.680 and non-TOF kappa = 0.457, CI 0.
278–0.636). For osseous metastasis detection, the inter-
reader agreement was good for TOF (TOF kappa = 0.
636, CI 0.453–0.810) and moderate for non-TOF (non-
TOF kappa = 0.600, CI 0.438–0.780).
Image quality
General image quality, image sharpness, and image noise
were rated statistically significantly superior (p value < 0.
001 for general quality and sharpness, p value < 0.05 for
noise) on TOF-PET reconstructions compared to non-
TOF-PET reconstructions, there was no significant dif-
ference in the rating of image artifacts (p value = 0.25)
(Fig. 5). Mean score (and SD) for TOF and non-TOF
sequences were 3.0 (± 0.7) and 2.6 (± 0.7) for general
quality, 3.1 (± 0.6) and 2.6 (± 0.7) for image sharpness, 2.
7 (± 0.7), 2.3 (± 0.7) for image noise, and 0.4 (± 0.6) and
0.5 (± 0.6) for artifacts. Details of all readers are given in
Additional file 1: Table S1.
Fig. 4 Images of a patient with a PET-positive lesion along the right external iliac vessel diagnosed as a lymph node metastasis of prostate cancer.
a Fusion image (left) and PET image (right) of simultaneous 18F-choline non-TOF PET/MR. b Fusion image (left) and PET image (right) of simultaneous
18F-choline TOF PET/MR. c T1-weighted MR image showing a normal-sized lymph node (arrow)
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Discussion
In the present study, we investigated the impact of non-
TOF versus TOF reconstruction in 18F-choline PET/MRI
on lesion detection in a clinical setting. We demonstrated
that not only SUV measurements are significantly affected,
but also the lesion detection rate is lower if PET data is
reconstructed without TOF information. Furthermore, we
compared SUV measurements of TOF and non-TOF re-
constructions in physiological osseous or pelvic tissue and
could confirm lower SUVmax values as previously found in
simulated data, suggesting that TOF can recover some of
the lost PET signal in areas under-corrected by the MRAC
that does not consider bone tissue.
Comparing TOF and non-TOF PET OSEM recon-
structions is not straightforward as TOF also acceler-
ates the convergence rate of the iterative algorithm.
Briefly, this means that TOF reconstructions converge
faster (requiring fewer iterations) to the “true” (or more
accurate) SUV. As each iteration adds more noise to
the image, fewer iterations also means lower image
noise. Finally, this can be interpreted as an improved
SNR or contrast recovery [23, 25]. This “TOF effect”
increases with improved TOF timing resolutions [50].
To avoid unacceptably noisy PET images, the OSEM
iterative process is usually stopped early. With the
injected dose and scan time applied in this study, both
the TOF and non-TOF OSEM reconstructions needed
to be stopped after two iterations. A consequence of the
early termination of the iterative process is that the
reconstructed PET images may have non-uniform recov-
ery of activity as different image parts may converge at
different rates. Using the same number of iterations in
both TOF and non-TOF OSEM means, considering the
faster convergence rate of TOF OSEM, that some TOF
OSEM reconstructed image parts have more accurate
(higher) SUV compared to the non-TOF OSEM recon-
structed images. These TOF effects are already known
from research on PET/CT. The application of TOF in
PET/MR has however additional effects as was briefly
mentioned in the introduction and indicated in this
study. Most of the previous comparison regarding SUV
measurements between TOF and non-TOF reconstruc-
tions has been done in PET/CT and showed improved
PET quantification using TOF [51–53]. There is only lit-
tle evidence that TOF reconstruction in PET/CT does
not have a clinically relevant impact on SUV measure-
ment [54]. Our data demonstrate that TOF PET/MRI
reconstruction results in higher SUVmax measurements
in physiological osseous structures as well as in lesions
within the prostate, bones, and lymph nodes compared
to non-TOF PET reconstructions. This is in concord-
ance to preliminary data shown in an abstract by
Mollard et al. who also found higher SUVmax in TOF
reconstructions compared to non-TOF reconstructions
in lesions in prostate patients with 18F-choline [55] and
is consistent with the findings of a simulation study of
Mehranian et al. [21].
Moreover, our results suggest that lymph node and
osseous metastases detection rate is higher on TOF PET
reconstructions compared to non-TOF PET reconstruc-
tions. Most of the previous patient studies evaluating
lesion detection comparing TOF and non-TOF PET
were achieved in PET/CT and suggested a better lesion
detection for TOF reconstructions [25, 26, 56–59].
Fig. 5 Image quality rating of TOF and non-TOF sequences
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Hausmann et al. [58], for example, found a higher lesion de-
tection rate in a study comparing TOF and non-TOF 18F-
choline in PET/CT in 32 prostate cancer patients with
biochemical recurrence. The gain in lesion detection due to
TOF in PET/CT is attributed to several factors, whereas an
improved signal to noise ratio and contrast to noise ratio is
considered to play an important role [35, 60], especially in
small lesions [57, 61, 62]. It is obvious that these factors are
also relevant for PET/MRI, while the correction of SUV
underestimation induced by MRAC plays an additional
important role. Our measurements suggest that SUV
underestimation does not only affect bone tissue but also
lesion in the proximity of bones, leading to a negative
correlation between relative difference in lymph node activity
and distance to osseous structures, as shown in Fig. 3. An
additional factor that could have influenced lesion detection
is reduced scatter correction artifacts around the bladder and
the liver/kidney in TOF, as previously described by
Minamimoto et al. [35] in PET/MR. Our results additionally
showed a higher interreader agreement for lymph node and
bone metastasis on TOF compared to non-TOF.
A direct comparison of lesion detection in TOF and
non-TOF PET/MRI in patients has not yet been re-
ported. Therefore, no direct comparison of our results is
possible. However, performance of choline PET/MRI
compared to PET/CT in prostate patients has been in-
vestigated previously in several studies using both TOF
capable PET/MRI [8, 9] and non-TOF PET/MRI [7, 12].
One study using TOF PET/MRI showed a higher lesion
detection rate compared to TOF PET/CT [8], while two
had equivocal results [9, 12] and one comparison of
TOF PET/CT with non-TOF PET/MRI had a slightly
higher detection rate on the TOF PET/CT (three lymph
nodes, one bone lesion) [7].
TOF plays an important role in current PET/MRI im-
aging for standard MR imaging-based attenuation cor-
rection. Furthermore, TOF information is essential for
promising emission-based attenuation correction tech-
niques that might become standard attenuation correc-
tion in PET/MRI in the near future [50, 63–65]. All
these improvements are important for an accurate PET
quantification to improve lesion detection sensitivity and
to establish comparable results among PET/CT and
PET/MRI systems.
Although a TOF OSEM reconstruction takes approxi-
mately twice as long as a non-TOF OSEM reconstruction
(3 m: 30 s vs 1 m: 45 s per bed on our system), the effect
on the clinical workflow is usually limited. Modern recon-
struction computers have sufficient computing power to re-
construct an average dataset in the same time as an average
patient scan. As modern reconstruction computers and
software are optimized for parallel processing on central
processing unit (GPU) and/or GPU cores, they are scalable
to most clinical requirements [60].
Our study has inherent limitations; the study population
including only 20 and rather heterogeneous patients does
not allow any conclusion on the overall accuracy of 18F-
choline PET/MRI for staging or restaging prostate cancer,
especially also given the heterogeneous reference standard
with histopathology not available for all PET-positive
lesions. However, bone metastases are usually not biopsied,
and since it was our main interest to show the effect of TOF
versus non-TOF on bony structures and metastasis, we
selected a high-risk patient cohort for this project. Conse-
quently, only a minority underwent surgical treatment or
histological confirmation of the PET findings. Therefore, we
did not report on sensitivity or specificity measurement of
18F-choline PET/MRI but rather pointed out the differences
for qualitative and quantitative assessments of TOF versus
non-TOF reconstructions. Our reported subjective image
quality data might be biased due to the inherent problem
that readers usually identify TOF and non-TOF reconstruc-
tions by its appearance in a blinded readout.
Conclusion
Our results show that TOF reconstruction of 18F-
choline PET/MRI increases SUV measurements in
physiological osseous structures as well as pelvic
malignancies compared to non-TOF reconstructions, es-
pecially in bony lesions or lymph nodes in the proximity
of bones. Furthermore, our study suggests a positive im-
pact on lesion detection rate for lymph node and bone
metastasis in prostate cancer patients if TOF reconstruc-
tion is applied to 18F-choline PET/MR.
Additional file
Additional file 1: Table S1. Results of image quality rating. (DOCX 12 kb)
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